Your browser doesn't support javascript.
loading
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.
Kim, S J; Shin, D-Y; Kim, J S; Yoon, D H; Lee, W S; Lee, H; Do, Y R; Kang, H J; Eom, H S; Ko, Y H; Lee, S H; Yoo, H Y; Hong, M; Suh, C; Kim, W S.
Affiliation
  • Kim SJ; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul Department of Medical Device Management and Research, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul.
  • Shin DY; Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul.
  • Kim JS; Department of Internal Medicine, Yonsei University College of Medicine, Seoul.
  • Yoon DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Lee WS; Department of Internal Medicine, Inje University College of Medicine, Inje University Busan Paik Hospital, Gaegumdong, Busanjingu, Busan, Republic of Korea.
  • Lee H; Hematology-Oncology Clinic, National Cancer Center, Goyang-city.
  • Do YR; Department of Hematology-Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu.
  • Kang HJ; Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul.
  • Eom HS; Hematology-Oncology Clinic, National Cancer Center, Goyang-city.
  • Ko YH; Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
  • Lee SH; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul.
  • Yoo HY; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul Samsung Biomedical Research Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul.
  • Hong M; Department of Pathology, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea.
  • Suh C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Kim WS; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul wskimsmc@skku.edu.
Ann Oncol ; 27(4): 712-8, 2016 Apr.
Article in En | MEDLINE | ID: mdl-26861608
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, T-Cell, Peripheral / PTEN Phosphohydrolase / Everolimus Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, T-Cell, Peripheral / PTEN Phosphohydrolase / Everolimus Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Country of publication: